Clinical Trial Update: Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 basket trial update for cord blood-derived NK cells engineered with IL-15 and TGFBR2 knockout, for relapsed/refractory lymphoid malignancies. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoid Malignancies
• Non-hodgkin Lymphoma

Drugs mentioned

• CAR.70-engineered IL15-transduced cord blood-derived NK cells with TGFBR2 knockout

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoid, Hodgkin Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING